Effect of Silibinin on Dyslipidemia and Glycemic Alteration Associated with Polycystic Ovarian Syndrome: An Experimental Study on Rats

References

• Orio F, Muscogiuri G, Nese C, et al. Obesity, type 2 diabetes mellitus and cardiovascular disease risk: an uptodate in the management of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2016;207:214–219. doi:10.1016/j.ejogrb.2016.08.026
   PubMed Web of Science ®Google Scholar
• Mu N, Zhu Y, Wang Y, Zhang H, Xue F. Insulin resistance: a significant risk factor of endometrial cancer. Gynecol Oncol. 2012;125(3):751–757. doi:10.1016/j.ygyno.2012.03.032
   PubMed Web of Science ®Google Scholar
• Lim SS, Kakoly NS, Tan JWJ, et al. Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression: metabolic syndrome in PCOS. Obes Rev. 2019;20(2):339–352. doi:10.1111/obr.12762
   PubMed Web of Science ®Google Scholar
• Cassar S, Misso ML, Hopkins WG, Shaw CS, Teede HJ, Stepto NK. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic–hyperinsulinaemic clamp studies. Hum Reprod. 2016;31(11):2619–2631. doi:10.1093/humrep/dew243
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981–1030. doi:10.1210/er.2011-1034
   PubMed Web of Science ®Google Scholar
• Nisenblat V, Norman RJ. Androgens and polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes. 2009;16(3):224–231. doi:10.1097/MED.0b013e32832afd4d
   PubMedGoogle Scholar
• Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes. 2002;26(7):883–896. doi:10.1038/sj.ijo.0801994
   PubMed Web of Science ®Google Scholar
• Kim JJ, Choi YM. Dyslipidemia in women with polycystic ovary syndrome. Obstet Gynecol Sci. 2013;56(3):137. doi:10.5468/ogs.2013.56.3.137
   PubMedGoogle Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106(25):3143–3421. doi:10.1161/circ.106.25.3143
   PubMed Web of Science ®Google Scholar
• Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab. 2005;90(6):3236–3242. doi:10.1210/jc.2004-1843
   PubMed Web of Science ®Google Scholar
• Ortiz-Flores AE, Luque-Ramírez M, Fernández-Durán E, Alvarez-Blasco F, Escobar-Morreale HF. Diagnosis of disorders of glucose tolerance in women with polycystic ovary syndrome (PCOS) at a tertiary care center: fasting plasma glucose or oral glucose tolerance test? Metabolism. 2019;93:86–92. doi:10.1016/j.metabol.2019.01.015
   PubMed Web of Science ®Google Scholar
• Chu C, Li D, Zhang S, et al. Role of silibinin in the management of diabetes mellitus and its complications. Arch Pharm Res. 2018;41(8):785–796. doi:10.1007/s12272-018-1047-x
   PubMed Web of Science ®Google Scholar
• Xu F, Yang J, Negishi H, et al. Silibinin decreases hepatic glucose production through the activation of gut–brain–liver axis in diabetic rats. Food Funct. 2018;9(9):4926–4935. doi:10.1039/C8FO00565F
   PubMed Web of Science ®Google Scholar
• Gobalakrishnan S, Asirvatham SS, Janarthanam V. Effect of silybin on lipid profile in hypercholesterolaemic rats. J Clin Diagn Res. 2016;10(4):FF01–05. doi:10.7860/JCDR/2016/16393.7566
   PubMedGoogle Scholar
• Deep G, Gangar SC, Oberlies NH, Kroll DJ, Agarwal R. Isosilybin A induces apoptosis in human prostate cancer cells via targeting Akt, NF-κB, and androgen receptor signaling. Mol Carcinog. 2010;49(10):902–912. doi:10.1002/mc.20670
   Web of Science ®Google Scholar
• Kafali H, Iriadam M, Ozardalı I, Demir N. Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian disease. Arch Med Res. 2004;35(2):103–108. doi:10.1016/j.arcmed.2003.10.005
   PubMed Web of Science ®Google Scholar
• Mvondo MA, Mzemdem Tsoplfack FI, Awounfack CF, Njamen D. The leaf aqueous extract of Myrianthus arboreus P. Beauv. (Cecropiaceae) improved letrozole-induced polycystic ovarian syndrome associated conditions and infertility in female Wistar rats. BMC Complement Med Ther. 2020;20(1):275. doi:10.1186/s12906-020-03070-8
   PubMedGoogle Scholar
• Kakadia N, Patel P, Deshpande S, Shah G. Effect of Vitex negundo L. seeds in letrozole induced polycystic ovarian syndrome. J Tradit Complement Med. 2019;9(4):336–345. doi:10.1016/j.jtcme.2018.03.001
   PubMedGoogle Scholar
• Kim EJ, Jang M, Choi JH, Park KS, Cho IH. An improved dehydroepiandrosterone-induced rat model of polycystic ovary syndrome (PCOS): post-pubertal improve PCOS’s features. Front Endocrinol. 2018;9:735. doi:10.3389/fendo.2018.00735
   PubMed Web of Science ®Google Scholar
• Nallathambi A, Bhargavan R. Regulation of estrous cycle by Cynodon dactylon in letrozole induced polycystic ovarian syndrome in Wistars albino rats. Anat Cell Biol. 2019;52(4):511. doi:10.5115/acb.19.114
   Web of Science ®Google Scholar
• Gambineri A, Patton L, Altieri P, et al. Polycystic ovary syndrome is a risk factor for type 2 diabetes. Diabetes. 2012;61(9):2369–2374. doi:10.2337/db11-1360
   PubMed Web of Science ®Google Scholar
• Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women 1. J Clin Endocrinol Metab. 1999;84(1):165–169. doi:10.1210/jcem.84.1.5393
   PubMed Web of Science ®Google Scholar
• Maliqueo M, Sun M, Johansson J, et al. Continuous administration of a P450 aromatase inhibitor induces polycystic ovary syndrome with a metabolic and endocrine phenotype in female rats at adult age. Endocrinology. 2013;154(1):434–445. doi:10.1210/en.2012-1693
   PubMed Web of Science ®Google Scholar
• Dellapasqua S, Colleoni M. Letrozole. Expert Opin Drug Metab Toxicol. 2010;6(2):251–259. doi:10.1517/17425250903540246
   PubMed Web of Science ®Google Scholar
• Mannerås L, Cajander S, Holmäng A, et al. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology. 2007;148(8):3781–3791. doi:10.1210/en.2007-0168
   PubMed Web of Science ®Google Scholar
• Jahan S, Munir F, Razak S, et al. Ameliorative effects of rutin against metabolic, biochemical and hormonal disturbances in polycystic ovary syndrome in rats. J Ovarian Res. 2016;9(1):86. doi:10.1186/s13048-016-0295-y
   Web of Science ®Google Scholar
• Ozcan Dag Z, Dilbaz B. Impact of obesity on infertility in women. J Turk Ger Gynecol Assoc. 2015;16(2):111–117. doi:10.5152/jtgga.2015.15232
   PubMed Web of Science ®Google Scholar
• Rojas J, Chávez M, Olivar L, et al. Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. Int J Reprod Med. 2014;2014:1–17. doi:10.1155/2014/719050
   Google Scholar
• Jahan S, Abid A, Khalid S, et al. Therapeutic potentials of Quercetin in management of polycystic ovarian syndrome using Letrozole induced rat model: a histological and a biochemical study. J Ovarian Res. 2018;11(1):26. doi:10.1186/s13048-018-0400-5
   Web of Science ®Google Scholar
• Zhao L, Mao Z, Brinton RD, Select A. Combination of clinically relevant phytoestrogens enhances estrogen receptor β-binding selectivity and neuroprotective activities in vitro and in vivo. Endocrinology. 2009;150(2):770–783. doi:10.1210/en.2008-0715
   PubMed Web of Science ®Google Scholar
• Jiang Y, Gong P, Madak‐Erdogan Z, et al. Mechanisms enforcing the estrogen receptor β selectivity of botanical estrogens. FASEB J. 2013;27(11):4406–4418. doi:10.1096/fj.13-234617
   PubMed Web of Science ®Google Scholar
• Ndeingang EC, Defo Deeh PB, Watcho P, Kamanyi A. Phyllanthus muellerianus (Euphorbiaceae) restores ovarian functions in letrozole-induced polycystic ovarian syndrome in rats. Evid Based Complement Alternat Med. 2019;2019:1–16. doi:10.1155/2019/2965821
   Web of Science ®Google Scholar
• Alsaggar M, Bdour S, Ababneh Q, El-Elimat T, Qinna N, Alzoubi KH. Silibinin attenuates adipose tissue inflammation and reverses obesity and its complications in diet-induced obesity model in mice. BMC Pharmacol Toxicol. 2020;21(1):8. doi:10.1186/s40360-020-0385-8
   Web of Science ®Google Scholar
• Kim BR, Seo HS, Ku JM, et al. Silibinin inhibits the production of pro-inflammatory cytokines through inhibition of NF-κB signaling pathway in HMC-1 human mast cells. Inflamm Res. 2013;62(11):941–950. doi:10.1007/s00011-013-0640-1
   PubMed Web of Science ®Google Scholar
• Podder B, Kim YS, Zerin T, Song HY. Antioxidant effect of silymarin on paraquat-induced human lung adenocarcinoma A549 cell line. Food Chem Toxicol. 2012;50(9):3206–3214. doi:10.1016/j.fct.2012.06.007
   PubMed Web of Science ®Google Scholar
• Xiang SK, Hua F, Tang Y, Jiang XH, Zhuang Q, Qian FJ. Relationship between serum lipoprotein ratios and insulin resistance in polycystic ovary syndrome. Int J Endocrinol. 2012;2012:1–4. doi:10.1155/2012/173281
   Web of Science ®Google Scholar
• Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001;111(8):607–613. doi:10.1016/S0002-9343(01)00948-2
   PubMed Web of Science ®Google Scholar
• Tóth B, Németh D, Soós A, et al. The effects of a fixed combination of berberis aristata and Silybum marianum on dyslipidaemia – a meta-analysis and systematic review. Planta Med. 2020;86(02):132–143. doi:10.1055/a-1063-1649
   Web of Science ®Google Scholar
• Deep G, Oberlies NH, Kroll DJ, Agarwal R. Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway. Oncogene. 2008;27(28):3986–3998. doi:10.1038/onc.2008.45
   Web of Science ®Google Scholar
• Liao EP. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med. 2012;125(10):S1–S2. doi:10.1016/j.amjmed.2012.05.001
   Web of Science ®Google Scholar
• Huseini HF, Larijani B, Heshmat R, et al. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res. 2006;20(12):1036–1039. doi:10.1002/ptr.1988
   PubMed Web of Science ®Google Scholar
• Chen K, Zhao L, He H, Wan X, Wang F, Mo Z. Silibinin protects β cells from glucotoxicity through regulation of the Insig-1/SREBP-1c pathway. Int J Mol Med. 2014;34(4):1073–1080. doi:10.3892/ijmm.2014.1883
   Web of Science ®Google Scholar
• Gu M, Zhao P, Huang J, et al. Silymarin ameliorates metabolic dysfunction associated with diet-induced obesity via activation of farnesyl X receptor. Front Pharmacol. 2016;7. doi:10.3389/fphar.2016.00345
   Web of Science ®Google Scholar